Ziprasidone chemical structure
Find information on thousands of medical conditions and prescription drugs.

Ziprasidone

Ziprasidone (Geodon®) was the fifth atypical antipsychotic to gain FDA approval. Ziprasidone is FDA approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Clinical trials were conducted in acute cases of mania. Long-term trials have not been conducted for acute bipolar symptoms. Any "hypersensitivity to the product" -- including any of the adverse events noted during clinical trials-- should be grounds for discontinuance. It has been approved for acute episodes indicative of bipolar type I. It has not been studied in adolescents or children (under age 10). more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

Such a trial has been ordered by the FDA as one condition during the approval process. The brand name (Geodon®) has been suggested to bring to mind the phrase 'down (don) to earth (geo)' referring to the goals of medication.

Pharmacology

Ziprasidone has a high affinity for dopamine, serotonin, and alpha-adrenergic receptors and a medium affinity for histaminic receptors. Ziprasidone is somewhat unique among the "atypicals" in that it also displays some inhibition of synaptic reuptake of serotonin and norepinephrine, although the clinical significance of this is unknown. The mechanism of action of ziprasidone is unknown. However it is theorized that its antipsychotic activity is mediated primarily by antagonism at dopamine receptors, specifically D2. Serotonin antagonism may also play a role in the effectiveness of ziprasidone, but the significance of 5-HT2A antagonism is debated among researchers. Antagonism at histaminic and alpha adrenergic receptors likely explains some of the side effects of ziprasidone, such as sedation and orthostasis.

Pharmacokinetics

The systemic bioavailability of ziprasidone administered intramuscularly is 100%, or 60%, administered orally with food. After a single dose intramuscular administration, the peak serum concentration typically occurs at about 60 minutes after the dose is administered, or earlier. Steady state plasma concentrations are achieved within one to three days. The mean half-life (T 1/2) ranges from two to five hours. Exposure increases in a dose-related manner and following three days of intramuscular dosing, little accumulation is observed.

Metabolism

Ziprasidone is hepatically metabolized by aldehyde reductase. Minor metabolism occurs via cytochrome P450 3A4. Medication that induce (e.g carbamazepine) or inhibit (e.g. ketoconazole) CYP3A4 have been shown to decrease and increase, respectively, blood levels of ziprasidone. There are no known induces or inhibitors of aldehyde reductase.

Adverse Events

Ziprasidone may increase the QTc interval in some patients and may increase the risk of a type of heart arrythmia known as torsades de pointes. Ziprasidone should be used cautiously in patients taking other medications likely to interact with ziprasidone or increase the QTc interval.

Adverse events reported for ziprasidone include sedation, insomnia, orthostasis, akathisia and other permanent extrapyramidal side-effects such as tardive dyskinesia. Rarely, temporary speech disorders may result.

The medication can cause any conceivable side effect. See the FDA label for more information.

Recently, the FDA required the manufacturers of all atypical antipsychotics to include a warning about the risk of hyperglycemia and Type II diabetes with atypical antipsychotics. Some evidence suggests that ziprasidone may not be as bad as some of the other atypical antipsychotics at causing insulin resistance and weight gain. In fact, in a trial of long term therapy with ziprasidone, overweight patients (BMI>27) actually had a mean weight loss overall. Ziprasidone, though, is not a weight loss drug. The weight loss reflected in this study on ziprsidone was really reflective of patients who had gained weight on other antipsychotics who were now trending back toward their baseline.

Read more at Wikipedia.org


[List your site here Free!]


More long-term atypical antipsychotic studies are needed. (Olanzapine, Ziprasidone, Aripiprazole). : An article from: Clinical Psychiatry News $5.95 Atypical antipsychotics offer modest therapeutic advantage. (Beyond Superior Side Effect Profile).(Brief Article) : An article from: Clinical Psychiatry News $5.95
Geodon for injection. (New & Approved).(treating acute agitation in schizophrenia) : An article from: Internal Medicine News $5.95 Ziprasidone Offers Long-Term Symptom Control.(in patients with schizophrenia) : An article from: Clinical Psychiatry News $5.95
Ziprasidone Ameliorates Tourette's Syndrome Tics.(Brief Article)(Statistical Data Included) : An article from: Family Practice News $5.95 Geodon.(NEW & APPROVED) : An article from: Internal Medicine News $5.95
High-dose ziprasidone effective for treatment-resistant schizophrenia.(Adult Psychiatry) : An article from: Clinical Psychiatry News $5.95 Ziprasidone may improve cognition in schizophrenia.(Adult Psychiatry)(research report) : An article from: Clinical Psychiatry News $5.95
Two drugs most effective in psychotic substance abusers. (Ziprasidone, Risperidone).(Brief Article) : An article from: Clinical Psychiatry News $5.95 FDA approves IM ziprasidone for acute agitation. (Intramuscular Olanzapine Could Be Next).(intramuscular) : An article from: Clinical Psychiatry News $5.95

Evaluating the reconstitution of intramuscular ziprasidone (Geodon) into solution
STABILITY Evaluating the reconstitution of intramuscular ziprasidone (Geodon) into solution. Ewing JD, Rund DA, Votolato NA. Ann Emerg Med 2004; 43(3): ...
Ziprasidone: Test your drug IQ
This drug for schizophrenia may help a patient who hasn't responded to other antipsychotics. Treating schizophrenia usually requires lifelong use of an ...
FDA warns against off-label use of antipsychotic drugs
The U.S. Food and Drug Administration (FDA) has released a warning to physicians and patients that off-label use of certain drugs called "atypical ...
Ziprasidone Ameliorates Tourette's Syndrome Tics - Brief Article - Statistical Data Included
Ziprasidone, a novel antipsychotic, may be effective in diminishing motor and vocal tics in children and adolescents with Tourette's syndrome or chronic ...
Meds alert: old schizophrenia drug stands up to new ones
A class of recently developed medications for schizophrenia has rapidly become psychiatrists' treatment of choice. Small, pharmaceutical company-funded ...
Use of atypical antipsychotic drugs in patients with dementia - Clinical Pharmacology
Increasingly, atypical antipsychotic drugs are prescribed for elderly patients with symptoms of psychosis and behavioral disturbances. These symptoms ...
E-FALCONS: a mnemonic for monitoring the prescribing of atypical antipsychotics
A typical antipsychotic medications are increasingly being prescribed for the treatment of multiple conditions associated with psychosis in older patients.
Atypical Antipsychotic Drug Warning
The Food and Drug Administration (FDA) has asked all manufacturers of atypical antipsychotic medications to add a warning statement to the products' labeling ...

Home Contact Resources Exchange Links ebay